Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 182

Sort by

Sort Order Select

Journal Articles

Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia

Evgeny Arons, Chin-Hsien Tai, Joshi Suraj, Yuelin Liu, Chi-Ping Day, Mark Raffeld, Liqiang Xi, Mory Gould, Isaac David Shpilman, Christopher C. Oakes, Seema Ali Bhat, Michael Rhodes Grever, Daniel Jones, Kerry A Rogers, Hao-Wei Wang, Constance M Yuan, S. Cenk Sahinalp, Robert J. Kreitman

Blood blood.2024026894.

https://doi.org/10.1182/blood.2024026894

Published: 2024

Includes: Supplemental data

Journal Articles

NGS-Based Immunoglobulin Gene Sequencing for Diagnosis and MRD Monitoring of Multiple Myeloma

Yuyue Ren, Ming Liu, Jiancheng Fang, Lianjie Wang, Liqian Yu, Yanming Xue, Weiwei Zhao, Juan Liu, Yinglan Jin, Yaoyao Tian, Liyan Chen, Panxiang Cao, Fang Wang, Hongxing Liu, Wei Wang

Blood (2024) 144 (Supplement 1): 3325.

https://doi.org/10.1182/blood-2024-209254

Published: 2024

Journal Articles

Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia

Evgeny Arons, Chin-Hsien Tai, Suraj Joshi, Yuelin Liu, Chi-ping Day, Mark Raffeld, Liqiang Xi, Hong Zhou, Mory Gould, Isaac Shpilman, Christopher C. Oakes, Seema A Bhat, Michael R. Grever, Kerry A. Rogers, Hao-Wei Wang, Constance M. Yuan, Cenk Sahinalp, Robert J. Kreitman

Blood (2024) 144 (Supplement 1): 1586.

https://doi.org/10.1182/blood-2024-204016

Published: 2024

Journal Articles

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2024-208300

Published: 2024

Journal Articles

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

Minghui Duan, Lan Ma, Qiuling Wu, Hong Liang, Wei Wang, Lijun Mu, Hai Lin, Hebing Zhou, Hong-xia Shi, Jinghua Wang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2024-201204

Published: 2024

Journal Articles

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2024-211343

Published: 2024

Journal Articles

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

Brynn B. Duncan, Sara K. Silbert, Alexander W. Rankin, Bonnie Yates, Lauren Little, Toni Foley, Hao-Wei Wang, Constance M. Yuan, Dana I. Delgado Colon, Yanyu Wang, Jon Inglefield, John A Ligon, Hannah W. Song, Steven L. Highfill, Haneen Shalabi, David F. Stroncek, Naomi Taylor, Nirali N. Shah

Blood (2024) 144 (Supplement 1): 680.

https://doi.org/10.1182/blood-2024-198259

Published: 2024

Journal Articles

A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia

Robert J. Kreitman, Hao-Wei Wang, Dana I. Delgado Colon, Hong Zhou, Evgeny Arons, Mark Raffeld, Liqiang Xi, Julie Feurtado, Lacey James, Raul C. Braylan, Katherine R. Calvo, Irina Maric, Constance M. Yuan

Blood (2024) 144 (Supplement 1): 863.

https://doi.org/10.1182/blood-2024-202793

Published: 2024

Journal Articles

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood (2024) 144 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2024-208684

Published: 2024

Journal Articles

Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)

Yunfei Chen, Ting Sun, Da Gao, Wei Wang, ZePing Zhou, Guangxun Gao, Yi Wang, Hu Zhou, Yanping Song, Yinghui Lai, Zhenyu Yan, Jinsong Yan, Jie Bai, Lei Zhang

Blood (2024) 144 (Supplement 1): 3937.

https://doi.org/10.1182/blood-2024-202716

Published: 2024

Journal Articles

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Qian Cheng, JingWen Tan, Rui Liu, Liqing Kang, Hongjia Zhu, Yi Zhang, Erhua Wang, Ying Li, Jian Zhang, Han Xiao, Rong He, Xiaoyan Lou, Nan Xu, Wei Wang, Zhou Yu, Minghao Li, Hongfei Gu, Lei Yu, Xin Li

Blood (2024) 144 (Supplement 1): 3447.

https://doi.org/10.1182/blood-2024-200516

Published: 2024

Journal Articles

Frequent Copy Gains of Viral LMP-1 Confers Radiosensitivity in Natural-Killer/T Cell Lymphoma

Jing Quan Lim, Dachuan Huang, Kelila Xin Ye Chai, Phyu The, Kerry May Huifen Lim, Wendy Lee, Liang Wei Wang, Nur Ayuni Muhammad Taib, Beng Hooi Phang, Wee-Joo Chng, Olaf Rötzschke, Jason Yongsheng Chan, Soon Thye Lim, Jin-Xin BEI, Siok-Bian Ng, Choon Kiat Ong

Blood (2024) 144 (Supplement 1): 2963.

https://doi.org/10.1182/blood-2024-192976

Published: 2024

Journal Articles

Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R 2 ) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study

Wei Wang, Xu Zhang, Qihui Li, Hua Yin, Xiubin Xiao, Jian Li, Wenrong Huang, Hongmei Jing, Yan Zhang

Blood (2024) 144 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2024-198294

Published: 2024

Journal Articles

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Andrew L. Feldman, Guangzhen Hu, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Jimena B. Gimenez, Farah M. Salama, Min Shi, Elías Campo, Wing Chung Chan, James R. Cook, Giorgio Inghirami, Elaine S. Jaffe, Ryan Morin, Phillipp W. Raess, Andreas Rosenwald, Kerry J. Savage, Louis M. Staudt, George W. Wright, Catalina Amador, Jan Delabie, Timothy C. Greiner, Javeed Iqbal, Laura K. Hilton, Sarah L. Ondrejka, German Ott, Stefania Pittaluga, Graham W. Slack, Susan L. Slager, Joo Y. Song, Hao-Wei Wang, Ahmed A. Aljudi, Stephen M. Ansell, Carlos Barrionuevo, James R. Cerhan, Jennifer R. Chapman-Fredricks, Weina Chen, Laurence de Leval, Alejandro A. Gru, David L. Jaye, Liuyan Jiang, Brad S. Kahl, Kennosuke Karube, Young Hyeh Ko, Eric Mou, Matthew J. Maurer, L. Jeffrey Medeiros, Roberto N. Miranda, Naoki Oishi, Perry M. Anamarija, Akira Satou, Xueju Wang, Ryan A. Wilcox, Xiaojun Wu, Tadashi Yoshino, Yu Zeng

Blood (2024) 144 (Supplement 1): 2974.

https://doi.org/10.1182/blood-2024-202410

Published: 2024

Journal Articles

A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis

Fengkui Zhang, Li Zhang, Miao Chen, Hongyan Tong, Xiaoni Li, Wei Wang, Li Liu, Geoffrey Ross

Blood (2024) 144 (Supplement 1): 2701.

https://doi.org/10.1182/blood-2024-210973

Published: 2024

Journal Articles

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Peng Liu, Junling Zhuang, Zhongjun Xia, Bingzong Li, Songfu Jiang, Yian Zhang, Wei Wang, Xiaoqin Chen, Xiaohui Zhang, Shujuan Zhou

Blood (2024) 144 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2024-209665

Published: 2024

Journal Articles

Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch

Alexandra E. Kovach, Sara K. Silbert, Annie Luong, Gerald Lu, Michael Lu, Hao-Wei Wang, Karen M Chisholm, Andrew Doan, Deepa Bhojwani, Adam Lamble, Nirali N. Shah, Chintan Parekh, Gordana Raca, Brent L. Wood

Blood (2024) 144 (Supplement 1): 2799.

https://doi.org/10.1182/blood-2024-198961

Published: 2024

Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood (2024) 144 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2024-204447

Published: 2024

Journal Articles

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Zhiming Li, Jun Fang, Huilai Zhang, Wei Wang, Hui Li, Hui Zhou, Liqun Zou, Hong Cen, Wen Shujuan, Wuping Li, Peng Sun, Panpan LIU, Hang Yang, Yu Wang

Blood (2024) 144 (Supplement 1): 6542.

https://doi.org/10.1182/blood-2024-204292

Published: 2024

Journal Articles

A Machine Learning Readmission Risk Prediction Model for Classical and Malignant Hematologic Disease

Angela Bailey, Wei Wang, Clarence Shannon, IV, Jared Huling, Christopher Tignanelli

Blood (2024) 144 (Supplement 1): 7536.

https://doi.org/10.1182/blood-2024-211172

Published: 2024

NARROW

Non-V600E BRAF mutations and treatment for Hairy Cell Leukemia

NGS-Based Immunoglobulin Gene Sequencing for Diagnosis and MRD Monitoring of Multiple Myeloma

Non-V600E BRAF Gene Alterations in Hairy Cell Leukemia

Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma

The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Initial Experience with CD19/CD22 BiCistronic CAR T-Cells in Children and Young Adults with Recurrent or Refractory B-Cell Malignancies

A Randomized Phase 2 Trial of 2nd-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Classic Hairy Cell Leukemia

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Frequent Copy Gains of Viral LMP-1 Confers Radiosensitivity in Natural-Killer/T Cell Lymphoma

Polatuzumab Vedotin, Rituximab and Lenalidomide (Pola-R 2 ) As First-Line Therapy for Unfit and Frail Elderly Diffuse Large B-Cell Lymphoma Patients: Preliminary Result of a Prospective, Phase II, Multi-Center Study

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Monocytic Differentiation in B-Lymphoblastic Leukemia with CRLF2 rearrangement at Diagnosis: Implications for Pathogenesis and Post-Therapeutic Lineage Switch

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

A Retrospective Analysis of Efficacy and Safety of Orelabrutinib Maintenance in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

A Machine Learning Readmission Risk Prediction Model for Classical and Malignant Hematologic Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only